Accolade, Inc. Stock Price, News & Analysis

Accolade, Inc. (Nasdaq: ACCD) launched a new healthcare category called Personalized Healthcare on Sept. 21, 2021, during its Evolve21 event. This initiative aims to enhance value-based care through three core pillars: Personal, Data driven, and Value based. New solutions include Accolade One and Accolade Care, focusing on integrated healthcare delivery. CEO Rajeev Singh emphasized the importance of human relationships in healthcare, addressing employee demands for better healthcare experiences. A SHRM survey highlighted that healthcare influences job change decisions for over half of U.S. employees.

Accolade, Inc. (Nasdaq: ACCD) will announce key updates during its annual customer event, Evolve21, on September 21, 2021. The event will be held virtually from September 21-23, 2021, and will feature an executive keynote session from 8:00am-10:00am PT, followed by a Q&A session from 10:15am-11:00am PT. Key speakers include CEO Rajeev Singh, SVP Umair Khan, and Chief Innovation Officer Mike Hilton. All sessions can be accessed through their official webcasts.

Accolade, Inc. (NASDAQ: ACCD) will announce its fiscal Q2 2022 financial results on October 7, 2021, post-market close. A conference call will follow at 4:30 p.m. E.T. for result discussions. Investors can join via phone or a live audio webcast available at their investor relations site. Accolade specializes in personalized health and benefits solutions aimed at improving health outcomes and reducing care costs for millions. The company maintains high consumer satisfaction ratings, exceeding 90%. For further details, investors may contact their investor relations team.

Accolade, Inc. (NASDAQ: ACCD) will participate in two upcoming investor conferences: the Morgan Stanley Virtual Global Healthcare Conference on September 9, 2021, at 8:45 a.m. E.T. and Baird’s 2021 Global Healthcare Conference on September 15, 2021, at 9:05 a.m. E.T. The company focuses on personalized health and benefits solutions, aiding individuals in managing healthcare complexities. Accolade boasts over 90% consumer satisfaction and aims to enhance health outcomes while reducing care costs. More details can be found at accolade.com.

Accolade, Inc. (NASDAQ: ACCD) will attend the 41st Annual Canaccord Genuity Growth Conference, featuring a presentation on August 12, 2021, at 11:00 a.m. E.T. An audio webcast and related materials will be accessible on their investor relations website. Accolade specializes in personalized health and benefits solutions, aiding individuals and employers in navigating healthcare complexities with a focus on lowering costs and improving outcomes. The company enjoys consumer satisfaction ratings exceeding 90%. For more information, visit their website or social media channels.

Accolade, Inc. reported a fiscal first quarter 2022 revenue of $59.5 million, a substantial 66% increase from $35.9 million in the same quarter of 2021. The company raised its fiscal year 2022 revenue guidance to $300 million - $305 million, reflecting a 78% increase year-over-year. However, the company also reported a net loss of $48.7 million, a 249% increase from the previous year's $14 million loss. Adjusted EBITDA was $(12.8) million, worsening by 36%. CEO Rajeev Singh highlighted strategic acquisitions and integrated care capabilities as keys to future growth.

Accolade, Inc. (NASDAQ: ACCD) announced the release of its fiscal first quarter 2022 financial results scheduled for July 8, 2021, post-market close. A conference call will be held at 4:30 p.m. E.T. to discuss these results, accessible via phone or a live audio webcast. Accolade focuses on personalized health and benefits solutions, aiming to empower individuals to achieve better health outcomes and reduce healthcare costs. The company has maintained high consumer satisfaction ratings over 90 percent.

Accolade, a leader in personalized healthcare, has acquired PlushCare for up to $450 million, enhancing its virtual primary care and mental health services. This deal, completed on June 9, 2021, includes $40 million in cash and $340 million in stock, with potential additional payments tied to revenue milestones. The acquisition is expected to broaden Accolade's market reach in a combined $200 billion addressable market, aiming for improved health outcomes while managing costs. The integration is projected to boost growth and generate new revenue opportunities.